<< NT-020 nutrients promote adult neural stem cell growth in aged rats: Researchers | Review shows how music training primes nervous system, boosts learning >>
Read in | English | Español | 日本語 | 简体中文 | Русский

BioStata invests in KIKA's Veracity advanced EDC platform

Published on July 21, 2010 at 6:07 AM · No Comments

KIKA™ Clinical Solutions, the leader in advanced EDC solutions for Clinical Asset Management™, announced that Denmark-based CRO BioStata ApS has made a seven-figure investment in KIKA technology to provide its Veracity™ advanced EDC platform to biopharmaceutical clients in Europe.

“Veracity addresses DMC and adjudication issues, which is of critical importance when dealing with life threatening circumstances”

BioStata specializes in statistics and worldwide EAC and DMC/DSMB services for pharmaceutical companies. It offers a complete SOP system and a large network of clinicians and statisticians to ensure a high level of service for companies under EMEA and FDA domain. BioStata signed a technology service agreement with KIKA last spring.

Bjarne Bodin, CEO of BioStata, said, "In our experience no other EDC platform offers Veracity™'s flexibility, capability and security, and KIKA improves the technology continually. We made this significant investment in the Veracity™ platform because it offers unique capabilities such as online event adjudication and because its team truly understands how to help pharmaceutical sponsors use eClinical technologies and strategies to conduct faster, safer, less expensive clinical trials. Together we are uniquely positioned to build a strong market."

Mr. Bodin added that BioStata ApS will move its headquarters to a larger office space near Copenhagen center, to accommodate the company's growth as more sponsors adopt eClinical technologies such as Veracity™.

KIKA's CEO Linda Beneze said, "Large pharmaceutical companies adopting DMC/DSMB need fail-safe, validated systems. BioStata's excellent CRO expertise combined with KIKA's advanced EDC platform will deliver a fail-safe solution that enables sponsors to make the best use of their clinical trial data."

Large pharmaceutical sponsors are adopting Veracity™ because it fits a critical need. They all struggle with the same problems. They need a reliable, automated data collection system to use across their major studies to free them from having to deal with time-consuming, expensive manual work such as adjudication, binding, and ensuring that documentation is complete and accurate.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading